PT3302454T - Composições para utilização no tratamento da doença de parkinson e distúrbios associados - Google Patents
Composições para utilização no tratamento da doença de parkinson e distúrbios associadosInfo
- Publication number
- PT3302454T PT3302454T PT167344811T PT16734481T PT3302454T PT 3302454 T PT3302454 T PT 3302454T PT 167344811 T PT167344811 T PT 167344811T PT 16734481 T PT16734481 T PT 16734481T PT 3302454 T PT3302454 T PT 3302454T
- Authority
- PT
- Portugal
- Prior art keywords
- disease
- compositions
- related disorders
- treating parkinson
- parkinson
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562166531P | 2015-05-26 | 2015-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3302454T true PT3302454T (pt) | 2021-04-01 |
Family
ID=56322267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167344811T PT3302454T (pt) | 2015-05-26 | 2016-05-25 | Composições para utilização no tratamento da doença de parkinson e distúrbios associados |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10471025B2 (pt) |
| EP (1) | EP3302454B1 (pt) |
| JP (1) | JP6853791B2 (pt) |
| CN (1) | CN107660147B (pt) |
| AU (1) | AU2016266432B2 (pt) |
| CA (1) | CA2986891C (pt) |
| ES (1) | ES2869981T3 (pt) |
| PT (1) | PT3302454T (pt) |
| WO (1) | WO2016190766A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3863712A4 (en) * | 2018-10-11 | 2022-07-20 | Indivior UK Limited | BUPRENORPHINE USED TO TREAT RESPIRATORY DEPRESSION |
| CA3124499A1 (en) * | 2018-12-24 | 2020-07-02 | Sorrento Therapeutics, Inc. | Method for treating parkinson's disease by administering resiniferatoxin |
| WO2022101227A1 (en) * | 2020-11-10 | 2022-05-19 | Integrative Research Laboratories Sweden Ab | [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (mesdopetam) for use in the prevention or reduction of sensitization to a pharmaceutical drug for parkinson's disease, in particular l-dopa induced dyskinesias |
| WO2022195529A1 (en) * | 2021-03-17 | 2022-09-22 | Sensedat S.R.L. | Device for predicting the wearing-off conditions in a patient affected by parkinson's disease |
| CN112933117B (zh) * | 2021-04-28 | 2023-04-07 | 遵义医科大学 | 一种预防和/或治疗帕金森病的药物及其应用 |
| US20240285664A1 (en) * | 2021-06-04 | 2024-08-29 | Transposon Therapeutics, Inc. | Line-1 inhibitors as cognitive enhancers |
| CN113422876B (zh) * | 2021-06-24 | 2022-05-10 | 广西电网有限责任公司 | 基于ai的电力客服中心辅助管理方法、系统及介质 |
| WO2023019351A1 (en) * | 2021-08-16 | 2023-02-23 | University Health Network | Methods and compositions for treating alpha-synuclein-mediated neurodegeneration |
| CN116832066B (zh) * | 2023-08-08 | 2024-01-12 | 青岛海洋生物医药研究院股份有限公司 | 乌贼墨提取物在制备抗多动症和抗抑郁症药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6071970A (en) | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| JP2006502234A (ja) * | 2002-09-17 | 2006-01-19 | モタック・ニューロサイエンス・リミテッド | ジスキネジーの治療 |
| WO2008079404A2 (en) | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
| EP1985292A1 (en) * | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
| EP2219633A2 (en) * | 2007-11-23 | 2010-08-25 | Nectid, Inc. | Tapentadol compositions |
| MX2010013393A (es) | 2008-06-06 | 2011-06-21 | Pharma Two B Ltd | Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson. |
| US8288592B2 (en) | 2009-09-22 | 2012-10-16 | Actavis Group Ptc Ehf | Solid state forms of tapentadol salts |
| JP5864606B2 (ja) * | 2010-12-28 | 2016-02-17 | ユーロ−セルティーク エス．エイ． | パーキンソン病の治療におけるオピオイド作動薬とオピオイド拮抗薬との組合せ |
| JP6040219B2 (ja) * | 2011-04-05 | 2016-12-07 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 三叉神経因性痛に伴う疼痛の治療用タペンタドール |
| DK2701693T3 (da) * | 2011-04-29 | 2017-11-13 | Gruenenthal Gmbh | Tapentadol til hindring og behandling af depression og angst |
| EA032064B1 (ru) * | 2013-03-15 | 2019-04-30 | Мелиор Фармасьютикалз Ii, Ллс | Способ лечения леводопа-индуцированной дискинезии с применением сиднокарба |
-
2016
- 2016-05-25 CN CN201680030076.6A patent/CN107660147B/zh active Active
- 2016-05-25 US US15/568,655 patent/US10471025B2/en active Active
- 2016-05-25 WO PCT/PT2016/050010 patent/WO2016190766A1/en not_active Ceased
- 2016-05-25 ES ES16734481T patent/ES2869981T3/es active Active
- 2016-05-25 AU AU2016266432A patent/AU2016266432B2/en active Active
- 2016-05-25 CA CA2986891A patent/CA2986891C/en active Active
- 2016-05-25 PT PT167344811T patent/PT3302454T/pt unknown
- 2016-05-25 EP EP16734481.1A patent/EP3302454B1/en active Active
- 2016-05-25 JP JP2017559872A patent/JP6853791B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2869981T3 (es) | 2021-10-26 |
| EP3302454B1 (en) | 2021-03-10 |
| US20180147160A1 (en) | 2018-05-31 |
| AU2016266432A1 (en) | 2017-11-09 |
| JP2018515549A (ja) | 2018-06-14 |
| US10471025B2 (en) | 2019-11-12 |
| CN107660147B (zh) | 2021-04-30 |
| CA2986891A1 (en) | 2016-12-01 |
| AU2016266432B2 (en) | 2020-10-22 |
| CN107660147A (zh) | 2018-02-02 |
| WO2016190766A1 (en) | 2016-12-01 |
| CA2986891C (en) | 2022-01-04 |
| JP6853791B2 (ja) | 2021-03-31 |
| EP3302454A1 (en) | 2018-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274648A (en) | Promote new catecholamine drugs for use in the treatment of Parkinson's disease | |
| SMT202400141T1 (it) | 8-ciano-5-piperidino-chinoline come antagonisti di tlr7/8 e loro usi per trattamento di disturbi immunitari | |
| IL277182A (en) | Compositions and methods for treating Parkinson's disease | |
| AU2022271491B2 (en) | Antisense oligonucleotides for use in treating alzheimer's disease | |
| IL263188B (en) | Treatment for Parkinson's disease | |
| EP3585373C0 (en) | Connections to the use in the treatment of Alzheimer's disease | |
| IL265911A (en) | Epilimod preparations and methods of using them in the treatment of Alzheimer's disease | |
| SMT202200151T1 (it) | Composizioni e metodi per l’uso nel trattamento di omocistinuria. | |
| EP3554496A4 (en) | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | |
| IL254252A0 (en) | History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease | |
| IL274203A (en) | A pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease | |
| PL3352742T3 (pl) | Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona | |
| IL265656A (en) | Preparations and methods for the treatment of Alzheimer's disease and Parkinson's disease | |
| EP3256151A4 (en) | Methods and compositions for treating muscle disease and disorders | |
| PL3166660T3 (pl) | Substancje i sposoby do zastosowania w profilaktyce i/lub leczeniu choroby Huntingtona | |
| EP3162377A4 (en) | Use of -asarone in preparing drugs for preventing and treating alzheimer's disease | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| ZA201806894B (en) | (+)-azasetron for use in the treatment of ear disorders | |
| GB201603510D0 (en) | Compositions for use in the treatment of neurological disease | |
| SG11201701618SA (en) | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders | |
| ZA201807944B (en) | Treatment for parkinson's disease | |
| HK40012465A (en) | Compositions and methods for treating alzheimer's disease and parkinson's disease | |
| GB201518052D0 (en) | Parkinson's disease treatment | |
| PT3442537T (pt) | (+)-azasetrom para utilização no tratamento de doenças do ouvido | |
| GB201504144D0 (en) | Treatment of Parkinson's disease |